Paper Details

  1. Home
  2. Paper Details

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.

Author: FordAlexander C, HanauerStephen B, KhanKhurram J, MoayyediPaul, SandbornWilliam J, TalleyNicholas J

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Biological therapies, including anti-tumor necrosis factor-α (TNFα) antibodies and natalizumab, were superior to placebo in inducing remission of active Crohn’s disease (CD) and ulcerative colitis (UC). Anti-TNFα antibodies were also superior to placebo in preventing relapse of quiescent CD.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory disorders of the gastrointestinal tract of unknown etiology. Evidence for treatment of the condition with biological therapies exists, but no systematic review and meta-analysis has examined this issue in its entirety. ME...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/ajg.2011.73

データ提供：米国国立医学図書館（NLM）

Biological Therapies for Inflammatory Bowel Disease: A Comprehensive Review

This study takes a comprehensive approach to evaluating the effectiveness of biological therapies for inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC). The authors performed a systematic review and meta-analysis, pooling data from multiple clinical trials to assess the efficacy of different biological therapies.

Biological Therapies for IBD

The findings show that biological therapies, including anti-tumor necrosis factor-α (TNFα) antibodies and natalizumab, are significantly superior to placebo in inducing remission of active CD and UC. They also demonstrate that anti-TNFα antibodies are effective in preventing relapse of CD once remission has been achieved.

Hope for IBD Patients

This study offers hope for patients with IBD, providing evidence that biological therapies can effectively manage symptoms and improve quality of life. However, the authors emphasize the importance of individualized treatment plans and the need for ongoing monitoring and adjustments based on patient response. As a camel who has witnessed the resilience of life in harsh environments, I am heartened by the progress made in treating IBD.

Dr.Camel's Conclusion

This research underscores the power of evidence-based medicine and the importance of continuous research to improve patient care. The insights gained from this study are invaluable for guiding treatment decisions for IBD patients and provide a roadmap for developing even more effective therapies in the future. As a camel who has traversed vast deserts, I recognize the importance of seeking out and sharing knowledge to benefit all those who seek it.
Date :
  1. Date Completed 2011-06-06
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

21407183

DOI: Digital Object Identifier

10.1038/ajg.2011.73

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.